MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sua, Jang, Shina, Kang, Jihoon, Park, Soo Bin, Han, Young Woo, Nam, Hyemi, Kim, Munkyung, Lee, Jeewon, Cho, Ki Joon, Kim, Jeonghun, Oh, Miyoung, Ryu, Jihye, Seok, Jong Hyeon, Kim, Yunhwa, Lee, Jee-Boong, Park, Man-Seong, Kim, Yong-Sung, Park, Hosun, Kim, Dong-Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637776/
https://www.ncbi.nlm.nih.gov/pubmed/34868052
http://dx.doi.org/10.3389/fimmu.2021.778829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637776/
https://www.ncbi.nlm.nih.gov/pubmed/34868052
http://dx.doi.org/10.3389/fimmu.2021.778829

Ejemplares similares